Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Health Care

57.95
+1.522.69%
Post-market: 57.950.00000.00%19:30 EDT
Volume:14.96K
Turnover:867.55K
Market Cap:96.78M
PE:- -
High:58.42
Open:57.85
Low:57.59
Close:56.43
52wk High:64.60
52wk Low:39.32
Shares:1.67M
Float Shares:1.67M
Volume Ratio:2.05
T/O Rate:0.90%
Dividend:0.71
Dividend Rate:1.22%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Growth Without AI: 8 Stock Picks

Dow Jones
·
Sep 11

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 11

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
Sep 11

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
Sep 11

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Sep 11

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Sep 11

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Reuters
·
Sep 10

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Sep 10

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

TIPRANKS
·
Sep 10

Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses

THOMSON REUTERS
·
Sep 10

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live
·
Sep 10